Kobe Ginobili
14年前
1,200 3mo. avg vol.
Contact Info
1 Dag Hammarskjold Blvd.
Freehold, NJ 07728
Website: http://www.speedus.com/
Phone: (888)-773-3669
Update Company Info
Business Description
Financial Reporting/Disclosure
Reporting Status Alternative Reporting Standard
Deregistered a/o Feb 16, 2011
Audited Financials Not Available
Latest Report Not Available
Regulatory Agency Not Available
CIK 0001002520
Fiscal Year End 12/31
OTC Market Tier OTC Pink No Information
Profile Data
SIC - Industry Classification 3841 - Surgical and medical instruments
Incorporated In: DE, USA
Year of Inc. Not Available
Employees Not Available
Company Officers
Shant S. Hovnanian President, CEO
Thomas M. Finn CFO, Secretary
Patrick Hodge IR
Company Directors
Not Available
Company Notes
Formerly=Speedus.com, Inc. until 6-02
Formerly=CellularVision USA, Inc. until 1-99
Service Providers
Auditor/Accountant
Not Available
Legal Counsel
Not Available
Investor Relations Firm
Not Available
SPDE Security Details
Share Structure
Market Value1 $4,995 a/o Sep 20, 2012
Shares Outstanding 4,162,326 a/o Nov 15, 2010
Float Not Available
Authorized Shares Not Available
Par Value 0.01
Shareholders
Shareholders of Record 200 a/o Mar 31, 2008
Security Notes
New & Secondary Issue=2-96 3,333,000 shs at $15 by Dillion, Read & Co. Inc. et al.
Capital Change=shs decreased by 1 for 4 split. Pay date=12/03/2007.
Short Selling Data
Short Interest 11,965 (0%)
Aug 31, 2012
Significant Failures to Deliver No
Transfer Agent(s)
State Street
jobynimble
16年前
Zargis Signs Agreement to Provide Ontario Telemedicine Network With Remote Stethoscope Solution
Wide-scale Implementation Within OTN's Network of 1,100+ Clinical Sites Anticipated
Sep 10, 2010 7:30:00 AM
STAMFORD, Conn., Sept. 10 /PRNewswire/ -- Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp. (OTCQB: SPDE), today announced that it has signed an agreement with the Ontario Telemedicine Network (OTN) providing for the delivery and testing of Zargis' award-winning telemedicine stethoscope system.
OTN is one of the world's largest and most respected telemedicine networks. An independent, not-for-profit organization funded by the Government of Ontario, Canada, OTN provides access to care for patients in every hospital in Ontario and hundreds of other healthcare locations across the province. In 2010 OTN will conduct more than 100,000 patient visits over more than 2,000 telemedicine systems.
The core component of Zargis' telemedicine stethoscope system, Zargis TeleSteth™, is a component of the Zargis Cardioscan heart sounds analysis software and the Zargis StethAssist® heart and lung sounds visualization software. TeleSteth was developed to extend the practice of auscultation (listening with a stethoscope) to situations and environments where face-to-face encounters are not always convenient or feasible. This platform allows healthcare professionals to share heart, lung and airway sounds with colleagues located across the globe using the Internet or a private network. TeleSteth permits patient sounds to be remotely evaluated in real-time (synchronous) or store-and-forward (asynchronous) mode.
TeleSteth is designed to be accessed from a user's PC via a standard Internet browser. Additionally, for organizations requiring users to access stethoscope sounds from within their private network, TeleSteth can be deployed using Zargis' secure enterprise server platform. All components of Zargis' telemedicine stethoscope system are HIPAA-compliant.
"OTN is one of the world's most sophisticated telemedicine networks and we are pleased to have been selected as the vendor of tele-auscultation solutions for their vast network of healthcare professionals throughout Canada's most populous province," stated Zargis CEO John Kallassy. "Zargis' tele-auscultation platform will help OTN deliver cost-effective, expert healthcare."
"OTN depends on reliable and easy-to-use equipment. Zargis' expertise in the field and the quality of their product met our need for a superior telemedicine stethoscope solution," said Dr. Ed Brown, OTN's CEO.
For more information about Zargis' tele-auscultation tools or to arrange a demonstration, call (609) 488-4608.
About Zargis Medical Corp.
Zargis is a global medical device company focused on improving health outcomes and cost-effectiveness through auscultation software and products. Zargis is majority-owned by Speedus Corp. (OTCQB: SPDE), and both 3M Company and Siemens Corporate Research, a division of Siemens AG (NYSE: SI), hold equity positions.
For additional information about Zargis or Speedus Corp., contact Peter Hodge at 888.773.3669 (ext. 23) or phodge@zargis.com, or visit the following Web sites: www.zargis.com and www.speedus.com.
Statements contained herein that are not historical facts, including but not limited to statements about the Company's product, corporate identity and focus, may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company, including, but not limited to, the continuing development of the Company's sales, marketing and support efforts.
SOURCE Speedus Corp.
----------------------------------------------
Peter Hodge for Speedus Corp.
+1-888-773-3669 (ext. 23)
phodge@zargis.com
Stock
16年前
Auscultate with Confidence™
Zargis has created the world’s first FDA-cleared medical software to identify and classify suspected systolic and diastolic heart murmurs. Zargis Cardioscan™, and the ZargisTelemed™ HIPAA-compliant tele-auscultation portal, have redefined what the stethoscope—the symbol of medicine—can do for you.
Learn more about our auscultation products
We identified the clinical need.
The human heartbeat. A symphony of sound that challenges us to hear, interpret and decide a course of action. The limits of our own subjective human perception and experience can inhibit us from hearing all the relevant clinical information each heartbeat may possess.
We developed the science.
Innovation is an amazing thing. By integrating advanced biomedical signal processing software with the Bluetooth®-enabled 3M™ Littmann® Electronic Stethoscope Model 3200, we now have the ability to explore the symphony of sounds behind every heartbeat.
And we turned that science into sound clinical tools.
Our decision-support tools are designed to enhance your clinical practice. As a company, our primary goal is to provide tools that enhance your clinical decision-making without disrupting your existing workflow.
jobynimble
16年前
http://ih.advfn.com/p.php?pid=nmona&article=42802250&symbol=SPDE
STAMFORD, Conn., May 13 /PRNewswire/ --
Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE), today announced that it has been selected by the U.S. Army's Telemedicine & Advanced Technology Research Center (TATRC) to present the Company's latest technologies at the TATRC exhibit during this year's American Telemedicine Association Conference (ATA), which takes place May 16-18 at the Henry B. Gonzalez Convention Center in San Antonio, TX.
"We are honored to have been selected by TATRC to present our industry leading medical devices at this premier conference," stated Zargis CEO, John Kallassy. "This presentation represents the first major marketing event for Zargis' new, award winning tele-auscultation platforms."
In addition to participating with TATRC at this conference, Zargis will also be demonstrating its newly introduced ZargisTelemed™ platform, which allows recordings from electronic stethoscopes to be easily transmitted between healthcare professionals via the Internet.
For more information about Zargis' tele-auscultation tools or to arrange a demonstration call 609-488-4608 begin_of_the_skype_highlighting 609-488-4608 end_of_the_skype_highlighting.
jobynimble
16年前
Density Dynamics Launches JetX10 Acceleration Appliance; Extreme-Performance With Scalability Beyond 1,000,000 IOPS
Jan 12, 2010 9:11:00 AM
GERMANTOWN, Md., Jan. 12 /PRNewswire/ -- Density Dynamics, a majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE), today announced the launch of the JetX10™—a breakthrough acceleration and optimization appliance that allows users to fully maximize and harness the speed of Jet.io™ Solid State Drives to dramatically improve the performance of any large computing or write-intensive environment.
Users of the fast and versatile JetX10 appliance will experience immediate performance improvements without application modification by utilizing JetX10 in a variety of computing environments, including:
-- Cloud Computing & Virtualization
-- Database Accelerator & Warehousing
-- Financial Transaction Applications
-- Tiered Storage Arrays
-- Business Intelligence Applications
-- GIS/Mapping Applications
Each JetX10 has a base configuration with Windows® Server 2008 R2 that supports up to four Jet.io drives and up to eight tiered SAS/SATA drives for storage. Expansion ports can be used for connectivity to a JetPOD/JetNODE expansion chassis or other available tiered storage chassis on a customized basis.
"The release of the JetX10 represents a significant achievement for Density Dynamics. By leveraging our experience and expertise in producing high-end solid state drives, we've developed a truly integrated and customizable appliance for enterprise clients," stated Density Dynamics CTO Dave Wilkerson. "The JetX10 provides users with an extremely powerful and fast single-rack performance solution to quickly and easily handle multiple tasks—such as data storage, or data mining—without the need to replace existing hardware, acquire new software or modify database functionality. We designed the Jet-X10 utilizing our Jet.io solid state drives as the core and added tiered hard drives to expand capacity and functionality. We have also priced the Jet-X10 competitively to deliver a highly compelling ROI to our customers."
About Density Dynamics
Density Dynamics, a majority owned subsidiary of Speedus Corp., is a pioneer in solid-state storage and I/O acceleration technology. Its high performance RamFlash solid-state storage and computing devices are designed to reduce I/O bottlenecks while also reducing power, cooling, and rack space requirements. Density Dynamics can be found on the web at www.densitydynamics.com.
About Speedus Corp.
Additional information on Speedus Corp. may be obtained at www.speedus.com or by contacting Peter Hodge at 888-773-3669 (ext. 23) or phodge@speedus.com.
Statements contained herein that are not historical facts, including but not limited to statements about the Company's product, corporate identity and focus, may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company, including, but not limited to, the continuing development of the Company's sales, marketing and support efforts.
CONTACT: Peter Hodge, +888-773-3669 (ext. 23), phodge@speedus.com
SOURCE Density Dynamics
----------------------------------------------
Peter Hodge
+1-888-773-3669 (ext. 23)
phodge@speedus.com
jobynimble
17年前
Zargis Cardioscan(TM) Featured on The Early Show on CBS
Nov 24, 2009 3:05:00 PM
STAMFORD, Conn., Nov. 24 /PRNewswire/ -- Zargis Medical Corp., a subsidiary of Speedus Corp. (Nasdaq: SPDE) and a spin-off from Siemens Corporate Research (NYSE: SI), today announced that its Zargis Cardioscan device was featured on the November 24, 2009 episode of CBS' The Early Show during a segment in which Mark Jannot, the editor of Popular Science magazine, reviewed five winning products from the publication's 2009 "Best of What's New" awards.
The Early Show is a widely-viewed television morning news talk show broadcast by CBS from New York City Monday through Saturday. A video clip of the "Best of What's New" awards segment can be viewed via the following link: http://tinyurl.com/Zargis-on-CBS.
As previously announced, 3M(TM) Health Care and Zargis Medical were jointly awarded "Innovation of the Year" by Popular Science for Zargis Cardioscan and the compatible 3M(TM) Littmann® Electronic Stethoscope Model 3200. During the segment on The Early Show, Mark Jannot described Cardioscan and the Model 3200 stethoscope as follows: "[It's] the same thing that you see around your doctor's neck every time you go to the doctor's office, but it's our Innovation of the Year because it's a really revolutionary diagnostic device. It sends your heart sounds by Bluetooth® to a nearby computer where software will analyze it to detect hard-to-find heart murmurs."
According to Peter Hodge, Zargis' marketing director, "We are very encouraged by the level of interest Zargis Cardioscan is receiving in the both the healthcare arena and the mainstream media, especially as we prepare for the international roll-out of the device."
About Zargis Cardioscan
Zargis Cardioscan is the first and only computer-assisted medical device designed to support physicians in analyzing heart sounds for the identification of suspected systolic and diastolic murmurs. Cardioscan is a non-invasive device that is easy to use, portable, and takes just minutes to perform. The device implements voice-guided protocol and a graphical user interface while maintaining an efficient physician workflow. Cardioscan provides a summary of findings in terms that are readily understood by physicians and offers an additional range of quantitative auscultatory information that cannot be obtained through listening alone. Cardioscan is intended to enhance auscultation -- a procedure that has been universally employed through a stethoscope for nearly two-hundred years.
About Zargis Medical Corp.
Zargis Medical Corp. develops advanced diagnostic decision support products and services for primary care physicians, pediatricians, cardiologists and other healthcare professionals. Zargis was formed in 2001 when Siemens Corporate Research, a division of Siemens AG (NYSE: SI), and Speedus Corp. co-invested to develop and market an advanced acoustic technology designed to detect heart abnormalities identified through analysis of heart sounds. Zargis and 3M(TM) (NYSE: MMM) jointly launched Cardioscan and the Model 3200 stethoscope in August 2009 as part of an exclusive global multi-year global marketing alliance.
For additional information about Zargis or Speedus Corp., contact Peter Hodge at 888.773.3669 (ext. 23) or phodge@zargis.com or visit the following Web sites: www.zargis.com and www.speedus.com.
Statements contained herein that are not historical facts, including but not limited to statements about the Company's product, corporate identity and focus, may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company, including, but not limited to, the continuing development of the Company's sales, marketing and support efforts.
SOURCE Zargis Medical Corp.
----------------------------------------------
Peter Hodge
1-888-773-3669 (ext. 23)
phodge@zargis.com
jobynimble
17年前
Zargis Cleared as Apple iPhone Developer; Medical Applications for Smartphones Planned
Oct 21, 2009 11:17:00 AM
STAMFORD, Conn., Oct. 21 /PRNewswire/ -- Zargis Medical Corp., a subsidiary of Speedus Corp. (Nasdaq: SPDE) and a spin-off from Siemens Corporate Research (NYSE: SI), today announced that is has been cleared as an Apple(®) iPhone(®) developer and has begun development of medical diagnostic support software and related peripherals for the iPhone and other leading smartphones.
Zargis has identified the handheld environment as a logical delivery platform for its telemedicine and diagnostic software initiatives, and with its team of experienced developer's plans to leverage the smartphone platform as a mobile hub between medical device peripherals and computer-aided diagnostic support located either locally or remotely.
A recent report released by Manhattan Research stated that 64% of doctors, more than double the number eight years ago, own smartphones, and that this figure will increase to 81% penetration in 2012. However, despite the rapid adoption of the iPhone and other smartphones by physicians, currently available healthcare applications for these devices are generally limited to medical reference libraries, educational tools and applications designed to manage patient medical records.
"The future of healthcare delivery is about connectivity and mobility. Zargis' expertise in computer-aided auscultation and our advanced medical software platform positions us perfectly to create diagnostic software and peripherals that are a natural fit for smartphones. We intend to improve healthcare efficiency by helping clinicians bring medical technology to the patient, rather than the other way around," stated Zargis CEO John Kallassy.
About Zargis Medical Corp.
Zargis Medical Corp. develops advanced diagnostic decision support products and services for primary care physicians, pediatricians, cardiologists and other healthcare professionals. Zargis was formed in 2001 when Siemens Corporate Research, a division of Siemens AG (NYSE: SI), and Speedus Corp. co-invested to develop and market an advanced acoustic technology designed to detect heart abnormalities identified through analysis of heart sounds.
For additional information about Zargis or Speedus Corp., contact Peter Hodge at 888.773.3669 (ext. 23) or phodge@zargis.com or visit the following Web sites: www.zargis.com and www.speedus.com.
Statements contained herein that are not historical facts, including but not limited to statements about the Company's product, corporate identity and focus, may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company, including, but not limited to, the continuing development of the Company's sales, marketing and support efforts.
iPhone and Apple are registered trademarks of Apple Inc.
SOURCE Zargis Medical Corp.
----------------------------------------------
Peter Hodge
+1-888-773-3669 (ext. 23)
phodge@zargis.com
jobynimble
17年前
Density Dynamics Develops Distribution; Signs International Rep Agreement
Sep 11, 2009 8:25:00 AM
GERMANTOWN, Md., Sept. 11 /PRNewswire/ -- Density Dynamics, a majority owned subsidiary of Speedus Corp. (Nasdaq: SPDE), announced today it has signed an International Representation agreement covering India with Graphay, Inc.
"We are excited to establish a sales and distribution channel for the cutting-edge DRAM-based SSD's built for high speed data enterprise users. My experience at Wachovia in the data center environment led me to witness the Jet.io SSD. Its power and performance capabilities are highly anticipated in the Indian market and together with Graphay's technologies, will address pressing needs of our Enterprise customers. We look forward to a long and fruitful relationship," said Ashish Majmundar, CEO and founder of Graphay.
About Density Dynamics
Density Dynamics, a majority owned subsidiary of Speedus Corp., is a pioneer in the solid-state storage and I/O acceleration technology. Its high performance RamFlash solid-state storage and computing devices are designed to reduce I/O bottlenecks while also reducing power, cooling, and rack space requirements. Density Dynamics can be found on the web at www.densitydynamics.com.
About Graphay
Graphay, headquartered in Matthews, NC, is an Enterprise IT Solutions Provider to customers in India & Israel. Graphay offers end-to-end architecture design, desktop and data center virtualization, along with best-in-breed products from its Global technology partners. Graphay can be found on the web at www.graphay.com.
About Speedus Corp.
Additional information on Speedus Corp. may be obtained at www.speedus.com or by contacting Peter Hodge at 888-773-3669 (ext. 23) or phodge@speedus.com.
Statements contained herein that are not historical facts, including but not limited to statements about the Company's product, corporate identity and focus, may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company, including, but not limited to, the continuing development of the Company's sales, marketing and support efforts.
SOURCE Density Dynamics
----------------------------------------------
Peter Hodge
+1-888-773-3669 (ext. 23)
phodge@speedus.com
jobynimble
17年前
SPDE/MMM
Zargis Cardioscan(TM) Unveiled Through Global Marketing and Distribution Alliance With 3M Company
Aug 25, 2009 8:00:00 AM
STAMFORD, Conn., Aug. 25 /PRNewswire-FirstCall/ -- Zargis Medical Corp., a spin-off from Siemens Corporate Research (NYSE: SI) and a majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE), today announced that it has begun selling its Zargis Cardioscan(TM) heart sound analysis software, along with 3M's (NYSE: MMM) just-released Bluetooth(R)-enabled 3M(TM) Littmann(R) Electronic Stethoscope Model 3200, as part of its previously announced exclusive multi-year global marketing alliance with 3M. This marketing alliance provides Zargis with a wide-range of global marketing and promotional opportunities along with exclusive rights to sell its products through the world-wide distribution network of the 3M(TM) Littmann(R) brand.
Zargis Cardioscan software, the 3M(TM) Littmann(R) Electronic Stethoscope Model 3200 and access to ZargisTelemed(TM) -- Zargis' Internet-based telemedicine portal -- can now be purchased online at www.zargis.com.
"The ability to record and automatically analyze heart sounds can help improve a clinician's confidence, document complex auscultations, and may keep some patients from going through additional, unnecessary testing," stated Joseph Tartaglia, MD, a practicing cardiologist in White Plains, NY, and clinical assistant professor of medicine at New York Medical College in Valhalla, NY.
Cardioscan heart sound analysis software is designed to support physicians in analyzing and interpreting cardiac sounds which can be signs of heart disease. Cardioscan connects wirelessly to the Bluetooth(R)-enabled 3M(TM) Littmann(R) Electronic Stethoscope Model 3200, and integrates with the ZargisTelemed portal -- a HIPAA-compliant feature of Cardioscan allowing users to easily share heart sounds recordings, analyzed results and comments with colleagues via the Internet.
"At a time when our nation is focused on leveraging technology to improve healthcare efficiency, these devices represents breakthroughs in auscultation that have the potential to reduce unnecessary referrals, and help clinicians detect pathologic heart murmurs earlier in the treatment cycle," stated John Kallassy, CEO of Zargis Medical. "We believe that the use of our software could enhance the physician experience during every patient exam where a stethoscope is used."
Zargis and select distributors of 3M(TM) Littmann(R) Brand Products will be selling Cardioscan for $395 (retail price) per licensed user -- a price point intended to make the device affordable to a variety of healthcare professionals around the world. In addition, access to the ZargisTelemed portal will be priced at $10 per month per licensed user.
About 3M Health Care
3M Health Care, one of 3M's six major business segments, provides world-class innovative products and services to help health care professionals improve the practice, delivery and outcome of patient care in medical, oral care, drug delivery and health information markets.
For more information, visit www.3M.com.
About Zargis Medical Corp.
Zargis Medical Corp. develops advanced diagnostic decision support products and services for primary care physicians, pediatricians, cardiologists and other healthcare professionals. Zargis was formed in 2001 when Siemens Corporate Research, a division of Siemens AG (NYSE: SI), and Speedus Corp. (Nasdaq: SPDE) co-invested to develop and market an advanced acoustic technology designed to detect heart abnormalities identified through analysis of heart sounds.
For additional information about Zargis or Speedus Corp., contact Peter Hodge at 888.773.3669 (ext. 23) or phodge@zargis.com, or visit the following Web sites: www.zargis.com and www.speedus.com.
Statements contained herein that are not historical facts, including but not limited to statements about the Company's product, corporate identity and focus, may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company, including, but not limited to, the continuing development of the Company's sales, marketing and support efforts.
SOURCE Speedus Corp.
----------------------------------------------
Peter Hodge for Zargis and Speedus Corp
1-888-773-3669 (ext. 23)
phodge@zargis.com
jobynimble
17年前
Quantitative Advantages of Next Generation RamFlash Design Released in White Paper; Density Dynamics Details Reliability Challenges of Flash Only SSD In High I/O Applications
Aug 11, 2009 8:00:00 AM
GERMANTOWN, Md., Aug. 11 /PRNewswire/ -- Density Dynamics, a majority owned subsidiary of Speedus Corp. (Nasdaq: SPDE), announced today it has published a new white paper detailing Reliability "Facts of Life" for HDD, Flash and Dram Drives in High Performance Storage Solutions. To download a copy, visit http://densitydynamics.com/resource-center.
About Density Dynamics
Density Dynamics, a majority owned subsidiary of Speedus Corp., is a pioneer in the solid-state storage and I/O acceleration technology. Its high performance RamFlash solid-state storage and computing devices are designed to reduce I/O bottlenecks while also reducing power, cooling, and rack space requirements. Density Dynamics can be found on the web at www.densitydynamics.com.
About Speedus Corp.
Additional information on Speedus Corp. may be obtained at www.speedus.com or by contacting Peter Hodge at 888-773-3669 (ext. 23) or phodge@speedus.com.
Statements contained herein that are not historical facts, including but not limited to statements about the Company's product, corporate identity and focus, may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company, including, but not limited to, the continuing development of the Company's sales, marketing and support efforts.
SOURCE Density Dynamics
----------------------------------------------
Peter Hodge
+888-773-3669 (ext. 23)
phodge@speedus.com
maddogs
17年前
The claims are some very bold statements by this company..
a place to get some industry back ground..
http://www.storagesearch.com/ssd-ram.html
"When flash SSDs aren't fast enough!
RAM based SSDs are the original type of solid state disk and have been around for decades.
They rely on batteries to retain data when power is lost. Most models also include internal hard disk drives to which data is saved under battery power, so that data is not lost when the battery runs down. This hybrid technology means that RAM based SSDs are more bulky than flash counterparts and RAM SSDs are unable to operate in the same range of hostile environments.
RAM based SSDs are mostly used in enterprise server speedup applications. The fastest RAM SSDs are faster than the fastest flash SSDs. But for many server speedup applications F-SSDs are fast enough.
Unlike flash SSDs, RAM based SSDs never had restrictions on the number of write cycles. That made them more popular in enterprise acceleration applications in the past. But write endurance problems may be a thing of the past for flash.
Like hard disks - RAM SSDs have symmetric read/write IOPS. That's another big difference between RAM and flash SSDs.
The fastest flash SSDs available in 2007 had narrowed the gap between R/W IOPS down to 10 to 1 (from over 50 to 1). And in 2008 - a small number flash SSD systems achieved 1 to 1. But random R/W IOPS for RAM SSDs, and latency are still an order of magnitude faster than the best flash SSDs.
There are also some non volatile memory products such as PRAM, FRAM and RRAM which are replacing flash in industrial applications - and which already offer 1 to 1 read/write performance. But their capacity is 2 orders of magnitude too low to be of use in server applications.
RAM SSDs cost about 25x as much as flash SSDs (based on pricing data for 3.5" form factor February 2008.)
The ideal choice of SSD depends on the specific server and application environment and cost / benefit analysis.
For example - a fibre-channel SSD that doubles the performance of a 100 server network may be overkill if your application runs on a single server box which could be speeded up by directly attached SSD storage."
If combining the benifits of Flash, Ram, size, memory retention, energy use and unit cost is where they say it is for their product, ,, one needs to understand how the monetization of the product would happen... Rights selling, licencing, direct sales and production , ect ect. to estimate cap of the company long term. Short term without any JV, partnerships ect., 20-50 mill seems about right imo. If they take a year to advance to mass production, competion will push
towards the lower (20 mill value), if a fast track is coming, the end cap (bold statements assumed true) cap could go over 50 mill easy (the company has not said they would be sharing a vertical plan with others that I know of yet). I believe most are hoping to see SPDE to come out of a boxed in practice of
sharing costs and rewards. Perhaps this spinoff will be the enabler.
Cap ex needs to be explained showing an avenue how expansion into the market will be paid for. Shelf, JV, mother company
could be the answer, with the small stock structure on this spinoff it would seem inappropriate to simply sell outright..
rights. Quite likely, there is a plan, looking for the company to fully explain it.
Like many of the Tech Bubble era this issue has declined from outragous highs, but they have had success before justifying $5 pps on a JV basis with a product having a lesser market in size.
http://www.zargis.com/product_overview.asp
"The Wall Street Journal Recognizes Zargis Medical With Technology Innovation Award
PRINCETON, NJ (September 11, 2006) – Zargis Medical Corp., a spin-off from Siemens Corporate Research (NYSE: SI) and a majority-owned subsidiary of Speedus Corp. (NASDAQ: SPDE), today announced that it was selected as a runner-up in The Wall Street Journal's 2006 Technology Innovation Awards. The competition honors breakthrough technologies from around the world in several categories.
As published in today’s Wall Street Journal, Zargis was selected as a runner-up in the Medical Devices.."
Hot Features
プレミアム
ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
Renee
5年前
ThoroughBread
10年前
AliAngel
17年前
メールアドレスで登録
